Jiangsu Wuzhong Pharmaceutical Group Corporation, a wholly-owned subsidiary of the company, was established in 2005. It has formed an integrated complete industrial chain covering genetic drugs, chemical drugs and modern traditional Chinese medicine, R&D, production and sales through asset merger and reorganization and enterprise internal integration. Wuzhong Pharmaceutical is Vice-President Unit of Jiangsu Provincial Pharmaceutical Association and President Unit of Suzhou Pharmaceutical Association, and ranked among the top 100 in comprehensive strengths of China ChemPharm Industry.

At present, Wuzhong Pharmaceutical Group owns solid production line foundation, gradually build key product group with the core of "anti-virus, anti-tumor, anti infection and immune regulation", of which “Marr-Arbidol Hydrochloride Tablets" have become the topped products.

Wuzhong Pharmaceutical Group establishes R&D institutions with Provincial Enterprise Technology Center, Jiangsu Gene Medicine Engineering Technology Research Center (Nanjing),Jiangsu Enterprise Academician Workstation, Jiangsu Wuzhong Suyao Pharmaceutical Development Co., Ltd.(Nanjing),Suzhou Zerun New Drug Research and Development Co., Ltd. and Wuzhong Pharmaceutical headquarter as the main bodies, builds a team of expert consultants and effectively creates a technology development platform and innovation system integrating the research, development and industrialization of genetic drugs, chemical drugs and modern Chinese medicines. The present key tasks are to focus on innovation and development of chemical and biological drugs and give great impetus to the consistency evaluation of injections, tablets and other varieties. Among them, Arbidol Hydrochloride Tablets has entered the 2019 edition of the national medical insurance catalog and became the anti-influenza virus drug officially recommended by the “National Health Commission's Influenza Diagnosis and Treatment Plan (2019 Edition)". Trimetazidine Dihydrochloride Tablets has passed the drug conformance evaluation as the first manufacturer, and has cooperated with Zhejiang University's high-level scientific research team to develop cancer treatment innovative medicine YS001, which is in smooth progress currently.

There are two production bases of Wuzhong Pharmaceutical Group. Suzhou Pharmaceutical Plant mainly produces active pharmaceutical ingredients, modern traditional Chinese medicines and chemical medicines, including hard capsules, granules, tablets (including anti-tumor drugs), oral solutions, dropping pills, emulsions, large-volume injections, and small-volumes injections, powder injections, freeze-dried powder injections and raw materials (including anti-tumor drugs) and other dosage forms. Zhongkai Biopharmaceutical Plant mainly produces biological products. In the meantime, Wuzhong Pharmaceutical forms multiple sales modes of terminal sales, distribution, investment attraction, OTC and so on. Its sales channels contain agents, medical institutions and retail pharmacies in all regions of the country.

In the future development, the company will concentrate superior resources, advance the strategy of big category, create several billion-level products, rapidly form the product layout of "Taking antiviral drugs as the core, backed by drugs for respiratory system, anti-tumor, digestive system and cardiovascular and cerebrovascular diseases". Meanwhile, traditional Chinese medicine will be treated as the important development direction and new growth point to realized the effective breakthrough in the aspects of operation scale and operation quality, so as to make the company become domestic leading pharmaceutical enterprise with outstanding innovation ability and advanced production capacity.